Recent Press Releases

U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate adjuvanted with Matrix-M™

Gaithersburg, MD (October 29, 2014)–/GlobeNewswire/-Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

Novavax Presents RSV F Protein Nanoparticle Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26

GAITHERSBURG, Md., Oct. 26, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections

MUNICH, Germany I October 28, 2014 I ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, announces today the completion of a EUR 7.5 million Series A financing...

Affinivax Launches Novel Conjugate Vaccine for Global Impact on Infectious Diseases

Investment from the Bill & Melinda Gates Foundation to Support Company Launch and Advance Lead Program targeting Pneumococcal Disease Exclusive License to Intellectual Property from Boston...

Novavax Announces Ebola Vaccine Development Program at the 8th Vaccine and ISV Conference in Philadelphia

GAITHERSBURG, Md., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX) today announced that Gale Smith, Ph.D., Vice President of Vaccine Development at Novavax, presented at the 8th Vaccine and...

Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA® (meningococcal group B vaccine)...

First vaccine approved by FDA to prevent serogroup B Meningococcal disease

The U.S. Food and Drug Administration announced today the approval of Trumenba, the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria...

CSL to acquire Novartis' influenza vaccine business

Melbourne, Australia — 27/10/2014 CSL Limited has today announced an agreement to acquire Novartis' global influenza vaccine business for US$275 million, which will be combined with...

Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million

Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million CSL to acquire Novartis influenza vaccines business, including development pipeline, for USD 275 million...

US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT:SAN and NYSE:SNY), announced today that the Biologics License...

Nation's largest distributor of influenza vaccines prepared to respond to vaccine delays

Despite multiple manufacturers experiencing delays, FFF has large quantities immediately available TEMECULA, Calif., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Unexpected delays from multiple manufacturers...

Vaxart's Tablet Vaccine for H1N1 Influenza Generates Protective Immunity Equivalent to Injectable in Phase I Clinical Study

Data Presented at World Vaccine Congress 2014 in Brussels SOUTH SAN FRANCISCO, CA, USA I October 14, 2014 I Vaxart, Inc., a privately held, clinical-stage company developing recombinant vaccines...

Baxter's Third Quarter Financial Results Exceed Guidance

Company Bolsters Portfolio, Achieves Significant Pipeline Milestones and Progresses Toward Separation DEERFIELD, Ill., October 16, 2014 - Baxter International Inc. (NYSE:BAX) today posted strong...

Ebola vaccine trials beginning in Mali

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced...

Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

Joint Support by Sanofi and JDRF Funds Ongoing Program for First-In-Class, Antigen-Specific Product to Target Autoimmunity Underlying Type 1 Diabetes WATERTOWN, Mass. – October 15, 2014...

Shantha's Investigational Rotavirus Vaccine Enters Phase III Clinical Trials in India

- The live, oral, ready-to-use tetravalent rotavirus vaccine candidate is designed to protect young children from severe diarrhea - Lyon, France - October 14, 2014 - Sanofi Pasteur, the vaccines...

Candidate H7N9 Avian Flu Vaccine Works Better with Adjuvant

Results of Large NIH-Sponsored Trial Published An experimental vaccine to protect people against H7N9 avian influenza prompted immune responses in 59 percent of volunteers who received two...

Takeda invests in Vaccine Safe Co., a subsidiary wholly-owned by Alfresa Corporation

Osaka, Japan, October 2, 2014 – Takeda Pharmaceutical Company Limited ("Takeda") announces today that it has decided to invest in Vaccine Safe Co. (Head Office: Chiyoda, Tokyo) which...

Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today it will present the results of a Phase 2, randomized study to evaluate co-administration of the company's investigational...

PNAS Modeling Study Finds TB Vaccines for Adolescents/Adults Cost-Effective Even With Low Efficacy

ROCKVILLE, MD, USA, OCTOBER 8, 2014 — A new study published in the Proceedings of the National Academy of Sciences released this week finds that a tuberculosis (TB) vaccine could have an...